CN101011436A - Medical usage of total phytosterone from achyranthes - Google Patents
Medical usage of total phytosterone from achyranthes Download PDFInfo
- Publication number
- CN101011436A CN101011436A CN 200710019605 CN200710019605A CN101011436A CN 101011436 A CN101011436 A CN 101011436A CN 200710019605 CN200710019605 CN 200710019605 CN 200710019605 A CN200710019605 A CN 200710019605A CN 101011436 A CN101011436 A CN 101011436A
- Authority
- CN
- China
- Prior art keywords
- achyranthes
- sterone
- total
- achyranthes bidentata
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及牛膝总甾酮在制药领域中的用途,尤其涉及在制备治疗或预防脂肪肝以及降脂减肥药物或保健品中的应用。牛膝总甾酮是指牛膝有效部位所含甾酮的总和,主要有蜕皮甾酮,牛膝甾酮,红苋甾酮等成分。研究发现服用牛膝总甾酮可用于治疗和预防脂肪肝以及降脂减肥,而且安全,毒副作用小。The present invention relates to the use of total sterone of Achyranthes bidentata in the field of pharmacy, in particular to the use in the preparation of medicines or health care products for treating or preventing fatty liver and lipid-lowering and weight-loss drugs. The total sterone of Achyranthes bidentata refers to the sum of sterones contained in the effective parts of Achyranthes bidentata, mainly including ecdysterone, achyranthes sterone, and amaranthus sterone. Studies have found that taking Achyranthes knuckle total sterone can be used for the treatment and prevention of fatty liver and fat-lowering weight loss, and it is safe and has little toxic and side effects.
Description
技术领域technical field
本发明涉及牛膝总甾酮在制药领域中的用途,尤其涉及在制备降脂减肥药物或保健品中的应用,以及在制备治疗或预防脂肪肝药物或保健品中的应用。The present invention relates to the use of total sterone of Achyranthes bidentata in the pharmaceutical field, in particular to the application in the preparation of fat-lowering and weight-loss drugs or health products, and the application in the preparation of drugs or health products for treating or preventing fatty liver.
背景技术Background technique
牛膝(Achyranthes bidentata BI.),又名怀牛膝,鸡胫骨,为苋科植物的根,多年生草本,栽培或野生于山野路旁,于冬季茎叶枯萎时采挖,去净须根、泥土,晒干切齐为药用。主产于湖南、湖北、河南、四川、贵州等地。牛膝系传统中药,其味甘苦酸,性平,入肝、肾经。具有补肝肾,强筋骨,活血通络的作用。主治:血滞经闭、痛经、月经不凋、跌打损伤、腰膝软、四肢拘挛、吐血、衄血、淋病尿血、牙龈肿痛、喉痹、痈肿等。甾酮是牛膝有效成分之一,主要有蜕皮甾酮、牛膝甾酮、红苋甾酮等。胥秀英、郑一敏、王龙撰写的《植物蜕皮激素的研究进度》(生物学杂志,2005.122(2):12~15页)公开了蜕皮甾酮的作用如下:给家兔口服蜕皮甾酮每天每只5~20mg,持续10~12周可显著抑制高胆固醇喂饲引起的血清总胆固醇及游离胆固醇的增加。Achyranthes bidentata BI., also known as Achyranthes bidentata BI., is the root of Amaranthaceae, a perennial herb, cultivated or wild on the side of mountain roads, excavated in winter when the stems and leaves are withered, and the fibrous roots and soil are removed , dried and cut into pieces for medicinal purposes. Mainly produced in Hunan, Hubei, Henan, Sichuan, Guizhou and other places. Achyranthes bidentata is a traditional Chinese medicine. Its taste is sweet and bitter, and its nature is flat. It enters the liver and kidney meridians. It has the functions of invigorating liver and kidney, strengthening muscles and bones, promoting blood circulation and dredging collaterals. Indications: blood stagnation amenorrhea, dysmenorrhea, menstrual bleeding, bruises, soft waist and knees, spasms of limbs, hematemesis, epistaxis, hematuria due to gonorrhea, gingival swelling and pain, sore throat, carbuncle, etc. Sterosterone is one of the active ingredients of Achyranthes bidentata, mainly including ecdysterone, achyranthes sterone, and amaranthus sterone. Xu Xiuying, Zheng Yimin, and Wang Long's "Research Progress of Plant Ecdysteroids" (Journal of Biology, 2005.122 (2): 12-15 pages) discloses the effect of ecdysterone as follows: give rabbits oral ecdysterone per day 5-20 mg, for 10-12 weeks, can significantly inhibit the increase of serum total cholesterol and free cholesterol caused by high-cholesterol feeding.
发明内容Contents of the invention
本发明的目的在于提供牛膝总甾酮的新用途,即在制备药物中的新应用。The object of the present invention is to provide a new application of the total sterone of Achyranthes bidentata, that is, a new application in the preparation of medicines.
为达到上述目的,本发明采用的第一种技术方案是:牛膝总甾酮在制备降脂减肥药物或保健品中的应用。特别是含量在50%以上的牛膝总甾酮在制备降脂减肥药物或保健品中的应用。所述“降脂减肥”中的“降脂”是指降低血脂。In order to achieve the above object, the first technical scheme adopted by the present invention is: the application of Achyranthes bidentata total sterone in the preparation of lipid-lowering and weight-loss drugs or health care products. In particular, the application of the total sterone of Achyranthes bidentata with a content of more than 50% in the preparation of lipid-lowering and weight-loss drugs or health care products. The "fat reduction" in the "fat reduction and weight loss" refers to the reduction of blood fat.
为达到上述目的,本发明采用的第二种技术方案是:牛膝总甾酮在制备治疗或预防脂肪肝药物或保健品中的应用。特别是含量在50%以上的牛膝总甾酮在制备治疗或预防脂肪肝药物或保健品中的应用。In order to achieve the above-mentioned purpose, the second technical scheme adopted by the present invention is: the application of Achyranthes bidentata total sterone in the preparation of medicines or health products for treating or preventing fatty liver. Especially the application of the total sterone of Achyranthes bidentata with a content of more than 50% in the preparation of medicines or health care products for treating or preventing fatty liver.
牛膝总甾酮是指牛膝有效部位所含甾酮的总和,主要有蜕皮甾酮,牛膝甾酮,红苋甾酮等成份。The total sterone of Achyranthes bidentata refers to the sum of sterones contained in the effective parts of Achyranthes bidentata, mainly including ecdysterone, sterone of achyranthes bidentata, and sterone of red amaranth.
我们在对牛膝总甾酮的研究中发现,牛膝总甾酮成份在人体内可以代谢为天然的雌性激素,这种雌性激素具有降脂减肥作用,特别是具有治疗或预防脂肪肝的作用。下面以动物试验(牛膝总甾酮对大鼠治疗或预防脂肪肝以及降脂减肥作用)加以说明:In our research on the total steroids of Achyranthes bidentata, we found that the total steroids of Achyranthes bidentata can be metabolized into natural estrogen in the human body. This estrogen has the effect of reducing fat and weight loss, especially for treating or preventing fatty liver . The animal experiment (Achyranthes knee total sterone has the effect of treating or preventing fatty liver and reducing fat and losing weight in rats) is described below:
SPF级SD雄性大鼠80只,体重180g~200g,大鼠于买回适应饲养1周后,从中随机抽取10只作为基础对照组,喂饲基础饲料[配方为:大麦粉20%、脱水菜(除去水份的包心菜)10%、豆粉20%、酵母1%、骨粉5%、玉米16%、麸皮16%、鱼粉10%、食盐2%],另外70只作为高脂组喂饲高脂饲料[即用酪蛋白代替配方中的豆粕后作为基础饲料,高脂饲料为76.2%基础饲料、12%大油、10%蔗糖、1.5%胆固醇、0.3%猪胆盐]。自由饮水与摄食2月后,按照喂饲高脂饲料大鼠的平均体重大于基础饲料组大鼠平均体重加1.4个标准差为肥胖大鼠的判断标准,筛选出肥胖模型大鼠40只。将此40只肥胖大鼠按体重随机分为肥胖对照组(灌胃生理盐水)和低、中、高3个牛膝总甾酮组(剂量分别为25mg/kg BW、50mg/kg BW及100mg/kgBW,灌胃给予)。各组均继续喂养高脂饲料,每周称重。4周后股动脉采血,检测各项指标。甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)以酶法用生化分析仪及配套试剂测定。采用SPSS12.0软件,数据以均数±标准差(x±s)来描述。80 male SD rats of SPF grade, weighing 180g-200g, after the rats were bought back and adapted to feeding for 1 week, 10 rats were randomly selected as the basic control group and fed with the basic feed [formula: barley flour 20%, dehydrated vegetables (Cabbage with moisture removed) 10%, soybean flour 20%, yeast 1%, bone meal 5%, corn 16%, bran 16%, fish meal 10%, salt 2%], and the other 70 were fed as high-fat group High-fat feed [i.e. use casein instead of soybean meal in formula as basic feed, high-fat feed is 76.2% basic feed, 12% large oil, 10% sucrose, 1.5% cholesterol, 0.3% pig bile salt]. After 2 months of free drinking and food intake, 40 obese model rats were screened out according to the criterion that the average body weight of the rats fed the high-fat diet was greater than the average body weight of the rats in the basal diet group plus 1.4 standard deviations. These 40 obese rats were randomly divided into obese control group (gastric administration of normal saline) and low, middle and high total sterone groups of Achyranthes bidentata by body weight (doses were respectively 25mg/kg BW, 50mg/kg BW and 100mg /kgBW, given by gavage). All groups continued to be fed high-fat diet and weighed every week. After 4 weeks, blood was collected from the femoral artery to detect various indicators. Triglyceride (TG), total cholesterol (TC), and high-density lipoprotein cholesterol (HDL-C) were determined by enzymatic method with a biochemical analyzer and supporting reagents. Using SPSS12.0 software, the data are described as mean ± standard deviation (x ± s).
表1 牛膝总甾酮对肥胖大鼠血脂的影响(mmol/L)Table 1 Effect of Achyranthes bidentata total sterone on blood lipids in obese rats (mmol/L)
注:与肥胖对照组比较,*P<0.05;与基础对照组比较,#P<0.05。Note: Compared with the obese control group, *P<0.05; compared with the basic control group, #P<0.05.
表2 牛膝总甾酮对高脂性脂肪肝大鼠肝组织中指标的影响(n=10)Table 2 Effect of Achyranthes bidentata total sterone on liver tissue indexes of rats with hyperlipidemia fatty liver (n=10)
注:与肥胖对照组比较,*P<0.05;n表示每组大鼠数量。Note: Compared with the obese control group, *P<0.05; n represents the number of rats in each group.
表1结果显示牛膝总甾酮在50mg/kg和100mg/kg时能够显著降低肥胖大鼠血液TG和TC水平,升高HDL-C水平。表2结果显示牛膝总甾酮能够显著降低高脂性脂肪肝大鼠肝组织中TG和TC的含量,同时降低肝重系数。以上结果清楚地表明:牛膝总甾酮对高脂性脂肪肝有较好的治疗效果。The results in Table 1 show that the total steroids of Achyranthes bidentata at 50 mg/kg and 100 mg/kg can significantly reduce the blood TG and TC levels of obese rats, and increase the HDL-C level. The results in Table 2 show that total steroids from Achyranthes bidentata can significantly reduce the content of TG and TC in the liver tissue of rats with hyperlipidemia fatty liver, and at the same time reduce the coefficient of liver weight. The above results clearly show that total sterone in Achyranthes bidentata has a good therapeutic effect on hyperlipidemia fatty liver.
表3 牛膝总甾酮对肥胖大鼠体重的影响(g)Table 3 Effect of Achyranthes bidentata total sterone on body weight of obese rats (g)
注:与肥胖对照组比较,*P<0.05。Note: Compared with the obese control group, *P<0.05.
表3显示牛膝总甾酮能够显著降低肥胖大鼠的体重,表现出很好的降脂减肥作用。Table 3 shows that the total sterone of Achyranthes bidentata can significantly reduce the body weight of obese rats, showing a good fat-lowering and weight-loss effect.
临床减肥实例:在减肥专科门诊中,选择37例单纯性肥胖症患者作为减肥实验志愿者进行疗效观察。诊断标准按照国际上使用最广泛的体重指数(BMI),即体重(kg)除以身高(m)的平方,采用亚洲成人体重分级的建议,即BMI 18.5~22.9为正常,≥23.0为超重,其中23.0~24.9为危险性增加,25.0~29.9为I度肥胖(中度),≥30.0为II度肥胖(严重)。患者年龄最小34岁,最大66岁,平均47岁;其中男11例,女26例;其中I度肥胖24例,II度肥胖13例。排除由下丘脑、肾上腺、垂体、甲状腺等病引起的继发性肥胖。治疗方法:口服自制牛膝总甾酮胶囊(含量为200-300mg/粒)每次2-3粒,每日3次,1个月为1个疗程,以2个月为限观察疗效。治疗结果:参照中国中西医结合肥胖病研究学组第三次修改制订标准:显效:治疗结束时体重下降5kg以上;有效:治疗结束时体重下降3~5kg;无效:治疗结束时体重下降未达上述标准者。37例单纯肥胖症患者中,显效11例:体重平均每月减轻3~6kg以上,血脂(主要是甘油三酯)明显下降;有效23例:体重平均每月减轻2~3kg,血脂比原来有所降低;无效3例:体重减轻不明显,每月在2kg以下甚至增重,血脂变化不明显。有效率为91.9%。Clinical weight loss example: In the weight loss specialist clinic, 37 patients with simple obesity were selected as volunteers for weight loss experiments to observe the curative effect. The diagnostic criteria are based on the most widely used body mass index (BMI) in the world, that is, the square of weight (kg) divided by height (m), and the recommendation of Asian adult weight classification, that is, BMI 18.5-22.9 is normal, ≥23.0 is overweight, Among them, 23.0-24.9 means increased risk, 25.0-29.9 means I degree obesity (moderate), and ≥30.0 means II degree obesity (severe). The youngest of the patients was 34 years old, the oldest was 66 years old, and the average age was 47 years old; 11 cases were male and 26 cases were female; 24 cases were of degree I obesity and 13 cases of degree II obesity. Secondary obesity caused by hypothalamus, adrenal, pituitary, thyroid and other diseases was excluded. Treatment method: Oral homemade Achyranthes bidentata total sterone capsules (content 200-300mg/capsule) 2-3 capsules each time, 3 times a day, 1 month as a course of treatment, and observe the curative effect within 2 months. Treatment results: refer to the third revision of China Obesity Research Group of Integrative Traditional Chinese and Western Medicine to formulate standards: markedly effective: weight loss of more than 5kg at the end of treatment; effective: weight loss of 3-5kg at the end of treatment; ineffective: weight loss at the end of treatment has not reached the above standards. Among the 37 patients with simple obesity, 11 cases were markedly effective: the average weight loss was more than 3-6 kg per month, and blood lipids (mainly triglycerides) decreased significantly; 3 cases of ineffectiveness: the weight loss was not obvious, and even the weight gain was below 2kg per month, and the change of blood lipid was not obvious. The effective rate is 91.9%.
总之,研究结果表明:作为药物时,采用口服方式服用牛膝总甾酮,可用于治疗和预防脂肪肝以及降脂减肥。服用量为15~35mg/kg·d-1,如果成人体重按70公斤计算,则服用量为1.0~2.5g/d-1。作为保健品时,成人服用量为0.2~0.3g/d-1即可。In conclusion, the research results show that: as a drug, oral administration of total sterone in Achyranthes can be used for the treatment and prevention of fatty liver as well as lipid-lowering and weight-loss. The dosage is 15-35 mg/kg·d -1 , if the adult body weight is calculated as 70 kg, the dosage is 1.0-2.5 g/d -1 . When used as a health product, the dosage for adults is 0.2-0.3g/d -1 .
牛膝总甾酮在制备治疗和预防脂肪肝以及降脂减肥药物或保健品时,主要制成口服剂型,如片剂、口服液、胶囊剂、粉剂、丸剂、颗粒剂等,其制药工艺均是成熟的技术,其剂型不影响疗效。Achyranthes bidentata total sterone is mainly made into oral dosage forms when preparing treatment and prevention of fatty liver and lipid-lowering and weight-loss drugs or health products, such as tablets, oral liquids, capsules, powders, pills, granules, etc., and its pharmaceutical process is It is a mature technology, and its dosage form does not affect the curative effect.
本发明的优点是:以牛膝总甾酮为主的有效部位,具有较好的治疗和预防脂肪肝以及降脂减肥作用,安全、毒副作用小。The invention has the advantages that: the active parts mainly contain the total sterone of Achyranthes bidentata, which has good effects of treating and preventing fatty liver, lowering fat and reducing weight, is safe, and has little toxic and side effects.
具体实施方式Detailed ways
下面结合实施例对本发明作进一步描述:The present invention will be further described below in conjunction with embodiment:
实施例一:Embodiment one:
1、牛膝总甾酮的制备1. Preparation of total sterone in Achyranthes bidentata
取牛膝饮片适量,按1kg药材20L水比例,在90~100℃水煮3次,每次2.5小时。过滤后收集牛膝提取液。上D型大孔吸附树脂柱,吸附流速1BV/min,至树脂吸附饱和。用水漂洗树脂至流出液澄清透明,用10BV(C2H5OH)=85%的乙醇洗脱,洗脱流速0.5BV/min,洗脱液烘干至恒重。即为牛膝有效部位,收率不少于0.15%(牛膝总甾酮含量60%以上)。Take an appropriate amount of Achyranthes knuckles decoction pieces, boil 3 times at 90-100°C for 2.5 hours each time according to the ratio of 1kg of medicinal materials to 20L of water. After filtering, the extract of Achyranthes bidentata was collected. Put on a D-type macroporous adsorption resin column, and the adsorption flow rate is 1BV/min until the resin is saturated. Rinse the resin with water until the effluent is clear and transparent, elute with 10BV (C 2 H 5 OH) = 85% ethanol at an elution flow rate of 0.5 BV/min, and dry the eluent to constant weight. It is the effective part of Achyranthes bidentata, and the yield is not less than 0.15% (the total sterone content of Achyranthes bidentata is more than 60%).
2、采用牛膝总甾酮制备成药剂,通过口服方式给人体服用,服用量控制在15~35mg/kg·d-1,如果成人体重按70公斤计算,则服用量为1.0~2.5g/d-1,具有较好的治疗和预防脂肪肝以及降脂减肥作用,而且安全,毒副作用小。药剂主要制成口服剂型,如片剂、口服液、胶囊剂、粉剂、丸剂、颗粒剂等,其制药工艺均是成熟的技术,其剂型不影响疗效。2. The total sterone of Achyranthes bidentata is used to prepare a medicament, and it is administered to the human body orally, and the dosage is controlled at 15-35 mg/kg·d -1 . If the adult body weight is calculated as 70 kg, the dosage is 1.0-2.5 g/kg/day. d -1 has good effects of treating and preventing fatty liver, lowering fat and losing weight, and is safe with less toxic and side effects. Medicines are mainly made into oral dosage forms, such as tablets, oral liquids, capsules, powders, pills, granules, etc. The pharmaceutical technology is mature technology, and the dosage forms do not affect the curative effect.
实施例二:将上述实施例一中制备的牛膝总甾酮制成保健品,通过口服方式给人体服用,服用量在0.2~0.3g/d-1,具有较好的预防脂肪肝以及降脂减肥作用,而且安全,毒副作用小。Embodiment 2: The total sterone of Achyranthes bidentata prepared in the above embodiment 1 is made into a health product, and it is taken orally to the human body, and the dosage is 0.2-0.3 g/d -1 , which has a good effect of preventing fatty liver and reducing Fat weight loss, and safe, with little side effects.
上述实施例只为说明本发明的技术构思及特点,其目的在于让熟悉此项技术的人士能够了解本发明的内容并据以实施,并不能以此限制本发明的保护范围。凡根据本发明精神实质所作的等效变化或修饰,都应涵盖在本发明的保护范围之内。The above-mentioned embodiments are only to illustrate the technical concept and characteristics of the present invention, and the purpose is to enable those skilled in the art to understand the content of the present invention and implement it accordingly, and not to limit the protection scope of the present invention. All equivalent changes or modifications made according to the spirit of the present invention shall fall within the protection scope of the present invention.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200710019605 CN101011436A (en) | 2007-01-20 | 2007-01-20 | Medical usage of total phytosterone from achyranthes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200710019605 CN101011436A (en) | 2007-01-20 | 2007-01-20 | Medical usage of total phytosterone from achyranthes |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101011436A true CN101011436A (en) | 2007-08-08 |
Family
ID=38699271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200710019605 Pending CN101011436A (en) | 2007-01-20 | 2007-01-20 | Medical usage of total phytosterone from achyranthes |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101011436A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8236359B2 (en) * | 2007-11-30 | 2012-08-07 | Institut Biophytis Sas | Use of phytoecdysones in the preparation of a composition for acting on the metabolic syndrome |
US20170071955A1 (en) * | 2011-11-10 | 2017-03-16 | Biophytis Sa | Method of stabilizing weight after a weight-loss diet using phytoecdysones |
US20170136041A1 (en) * | 2011-12-13 | 2017-05-18 | Biophytis Sa | Method of improving the muscle quality of obese and/or sarcopenic mammals using phytoecdysones |
-
2007
- 2007-01-20 CN CN 200710019605 patent/CN101011436A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8236359B2 (en) * | 2007-11-30 | 2012-08-07 | Institut Biophytis Sas | Use of phytoecdysones in the preparation of a composition for acting on the metabolic syndrome |
AU2008332981B2 (en) * | 2007-11-30 | 2014-06-12 | Biophytis | Use of phytoecdysones in the preparation of a composition for acting on metabolic syndrome |
US20170071955A1 (en) * | 2011-11-10 | 2017-03-16 | Biophytis Sa | Method of stabilizing weight after a weight-loss diet using phytoecdysones |
US20170136041A1 (en) * | 2011-12-13 | 2017-05-18 | Biophytis Sa | Method of improving the muscle quality of obese and/or sarcopenic mammals using phytoecdysones |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1964730B (en) | Herbal compositions for prevention and treatment rheumatic and inflammatory diseases and method of preparing the same | |
CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
WO2013010383A1 (en) | Intestine-hydrating and laxative drink and preparation method therefor | |
CN112245443A (en) | Composition of ginsenoside Rg3 and Rg5 and its anti-tumor medicine | |
WO2021213230A1 (en) | Application of traditional chinese medicine composition in preparation of drug for treating or preventing fatty liver disease | |
EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
CN100467031C (en) | Medicinal application of total lignans from burdock fruit | |
CN101810636A (en) | Application of Chinese yam polysaccharide in preparation of medicine for treating obesity | |
CN111110733B (en) | Traditional Chinese medicine composition for treating senile gouty arthritis and preparation method and application thereof | |
CN112439018A (en) | Composition with weight-losing and lipid-lowering functions as well as preparation method and application thereof | |
CN101011436A (en) | Medical usage of total phytosterone from achyranthes | |
CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
CN103083429B (en) | Blood fat-reducing traditional Chinese medicine formula | |
WO2014134833A1 (en) | Edible composition, preparation method therefor, and food product comprising the composition | |
CN101317900A (en) | Traditional Chinese medicine composition for preventing and treating alcoholic liver injury and preparation method thereof | |
CN112057535A (en) | Preparation method of traditional Chinese medicine composition for preventing or/and treating dyslipidemia | |
CN101002808A (en) | Medical use of bidentate achyanthes total sterone | |
WO2004084924A1 (en) | Pharmaceutical composition for treatment of bph and preparation thereof | |
CN114533835B (en) | A Chinese medicinal composition with effects of removing pathogenic wind and dampness, and its preparation method | |
CN103784683A (en) | Traditional Chinese medicinal composition for treating obesity and preparation method and application thereof | |
CN112089783B (en) | Application of traditional Chinese medicine composition in the preparation of medicine for preventing or/and treating obesity | |
CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
CN111905017A (en) | A kind of Chinese medicine composition and application of anti-Helicobacter pylori | |
KR100450055B1 (en) | Food composition for improving physical constitution containing seeds of bean plants as main components, and food produced therefrom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070808 |